Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis

Zahoor Ahmad, Austin Minkowski, Charles A. Peloquin, Kathy N. Williams, Khisimuzi E. Mdluli, Jacques H. Grosset, Eric L. Nuermberger

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

DC-159a is a new fluoroquinolone with more potent in vitro activity than available fluoroquinolones against both drug-susceptible and fluoroquinolone-resistant Mycobacterium tuberculosis. Here, we report that DC-159a displays pharmacokinetics similar to those of moxifloxacin yet is more active than moxifloxacin during both the initial and continuation phases of treatment in a murine model. These results warrant further preclinical evaluation of DC-159a in selected drug combinations against drug-susceptible and fluoroquinolone-resistant tuberculosis.

Original languageEnglish (US)
Pages (from-to)1781-1783
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume55
Issue number4
DOIs
StatePublished - Apr 2011

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis'. Together they form a unique fingerprint.

Cite this